Reporter brief
METforMIN: Metformin Administration for the Minimization of Geographic Atrophy Progression in Patients With Age-related Macular Degeneration
What happened
Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- This abstract provides no results—it is only a statement of purpose, so no effectiveness or safety conclusions can be drawn
- No information is given on study duration, follow-up period, or outcome measures, preventing assessment of what was actually measured
- The RCT design is stated but critical details (sample size, participant allocation, outcomes achieved) are absent, so the study's actual conduct and findings remain unknown
Study design and sample
Rct; Human.
Non-diabetic patients with Age-related Macular Degeneration (AMD)
- Design
- Rct
- Sample
- —
- Journal
- University of California, San Francisco
- Published
- Jun 9, 2023
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Metformin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.